Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNASDAQ:ALECNASDAQ:AMLXNASDAQ:ATHANASDAQ:COYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$195.15+0.8%$196.46$153.58▼$218.66$345.22B0.556.05 million shs8.39 million shsALECAlector$1.20+6.2%$1.25$0.87▼$6.78$118.90M0.73797,265 shs1.54 million shsAMLXAmylyx Pharmaceuticals$5.11+4.3%$3.79$1.58▼$7.27$436.51M-0.531.24 million shs1.04 million shsATHAAthira Pharma$0.28-6.1%$0.31$0.22▼$3.67$10.99M3.051.48 million shs161,416 shsCOYACoya Therapeutics$6.59+8.0%$6.17$4.65▼$10.24$110.22M0.4972,462 shs49,093 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+0.83%+10.08%-7.00%+11.17%+19.95%ALECAlector+6.19%+3.45%-2.44%-30.23%-76.38%AMLXAmylyx Pharmaceuticals+4.29%+0.99%+44.35%+45.58%+182.32%ATHAAthira Pharma-6.13%-2.15%+0.57%-47.27%-85.71%COYACoya Therapeutics+8.03%+0.46%+1.85%+12.46%-27.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.6165 of 5 stars2.44.04.23.92.72.51.3ALECAlector3.6465 of 5 stars3.11.00.04.53.01.70.6AMLXAmylyx Pharmaceuticals3.0347 of 5 stars3.41.00.00.02.84.21.3ATHAAthira Pharma3.2147 of 5 stars3.05.00.00.03.31.71.3COYACoya Therapeutics2.0037 of 5 stars3.53.00.00.02.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.89Moderate Buy$211.418.33% UpsideALECAlector 2.14Hold$3.50191.67% UpsideAMLXAmylyx Pharmaceuticals 2.86Moderate Buy$8.0056.56% UpsideATHAAthira Pharma 2.00Hold$13.834,812.41% UpsideCOYACoya Therapeutics 3.00Buy$17.00157.97% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, ALEC, ABBV, ATHA, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$214.00 ➝ $216.004/28/2025ABBVAbbVieEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$204.00 ➝ $205.004/28/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$241.00 ➝ $250.004/28/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/22/2025ABBVAbbVieCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$210.004/22/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/17/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$214.00 ➝ $214.004/11/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/9/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$239.00 ➝ $241.004/8/2025ABBVAbbVieThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Neutral$194.004/7/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$3.00 ➝ $7.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.13$14.42 per share13.53$1.90 per share102.71ALECAlector$100.56M1.18N/AN/A$1.41 per share0.85AMLXAmylyx Pharmaceuticals$87.37M5.21$0.93 per share5.51$6.42 per share0.80ATHAAthira PharmaN/AN/AN/AN/A$3.42 per shareN/ACOYACoya Therapeutics$3.55M31.01N/AN/A$2.47 per share2.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3581.3113.961.627.59%296.28%12.65%N/AALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%5/6/2025 (Estimated)AMLXAmylyx Pharmaceuticals$49.27M-$4.44N/AN/AN/AN/A-36.97%-29.61%5/8/2025 (Estimated)ATHAAthira Pharma-$117.67M-$2.53N/AN/AN/AN/A-115.62%-88.94%5/13/2025 (Estimated)COYACoya Therapeutics-$7.99M-$0.98N/AN/AN/AN/A-31.63%-27.76%5/8/2025 (Estimated)Latest AMLX, ALEC, ABBV, ATHA, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025ATHAAthira Pharma-$0.20N/AN/AN/AN/AN/A5/14/2025Q1 2025ALECAlector-$0.46N/AN/AN/A$4.25 millionN/A5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.43N/AN/AN/AN/AN/A5/8/2025Q1 2025COYACoya Therapeutics-$0.44N/AN/AN/AN/AN/A4/25/2025Q1 2025ABBVAbbVie$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 million3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) million2/27/2025Q4 2024ATHAAthira Pharma-$0.45-$0.39+$0.06-$0.39N/AN/A2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.36%+6.04%279.15%53 YearsALECAlectorN/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals$1.0219.88%N/AN/A N/AATHAAthira PharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ALatest AMLX, ALEC, ABBV, ATHA, and COYA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55ALECAlectorN/A3.293.29AMLXAmylyx PharmaceuticalsN/A4.554.55ATHAAthira PharmaN/A2.952.95COYACoya TherapeuticsN/A15.3115.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ALECAlector85.83%AMLXAmylyx Pharmaceuticals95.84%ATHAAthira Pharma57.12%COYACoya Therapeutics39.75%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%ALECAlector9.10%AMLXAmylyx Pharmaceuticals11.70%ATHAAthira Pharma19.80%COYACoya Therapeutics12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableALECAlector27099.09 million89.02 millionOptionableAMLXAmylyx Pharmaceuticals20089.08 million60.53 millionOptionableATHAAthira Pharma4039.04 million31.01 millionOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionableAMLX, ALEC, ABBV, ATHA, and COYA HeadlinesRecent News About These CompaniesCoya Therapeutics (NASDAQ:COYA) Receives "Buy" Rating from Chardan CapitalApril 30 at 8:33 AM | marketbeat.comIs Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?April 29 at 10:40 AM | zacks.comCoya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with ...April 26, 2025 | businesswire.comCoya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data ReleaseApril 25, 2025 | seekingalpha.comCoya Therapeutics reports interim results from IL-2, CTLA4-Ig combination studyApril 25, 2025 | markets.businessinsider.comPromising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline PotentialApril 25, 2025 | tipranks.comCoya Therapeutics' (COYA) "Buy" Rating Reiterated at D. Boral CapitalApril 24, 2025 | marketbeat.comCoya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection ...April 23, 2025 | seekingalpha.comWall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?April 23, 2025 | zacks.comCoya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher - What's Next?April 23, 2025 | marketbeat.comWhy Coya Therapeutics, Inc.’s (COYA) Stock Is Up 6.94%April 21, 2025 | aaii.comAtea Pharmaceuticals appoints Howard Berman to board of directorsApril 17, 2025 | markets.businessinsider.comIs Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 11, 2025 | insidermonkey.comIs Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 11, 2025 | msn.comWhat Makes Coya Therapeutics, Inc. (COYA) a New Buy StockMarch 27, 2025 | zacks.comWall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a BetMarch 27, 2025 | zacks.comCoya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome ProgramMarch 26, 2025 | businesswire.comCoya Therapeutics Reports 2024 Financial Results and ProgressMarch 21, 2025 | tipranks.comCoya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth PlansMarch 20, 2025 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comCoya Therapeutics Reports 2024 Financial Results and UpdatesMarch 18, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s LeadBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentBerkshire Hathaway Gains Defy Stock Market Slump By Jeffrey Neal Johnson | April 1, 2025View Berkshire Hathaway Gains Defy Stock Market Slump If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBy Thomas Hughes | April 25, 2025View If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To BuyBuffett Trims Equities, But Still Keeps Buying This Stock By Jea Yu | April 1, 2025View Buffett Trims Equities, But Still Keeps Buying This Stock AMLX, ALEC, ABBV, ATHA, and COYA Company DescriptionsAbbVie NYSE:ABBV$195.15 +1.64 (+0.85%) As of 04/30/2025 03:59 PM EasternAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Alector NASDAQ:ALEC$1.20 +0.07 (+6.19%) As of 04/30/2025 04:00 PM EasternAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Amylyx Pharmaceuticals NASDAQ:AMLX$5.11 +0.21 (+4.29%) As of 04/30/2025 04:00 PM EasternAmylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Athira Pharma NASDAQ:ATHA$0.28 -0.02 (-6.13%) As of 04/30/2025 04:00 PM EasternAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Coya Therapeutics NASDAQ:COYA$6.59 +0.49 (+8.03%) As of 04/30/2025 04:00 PM EasternCoya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
